|
業務類別
|
Diagnostics & Research |
|
業務概覽
|
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US. |
| 公司地址
| 322 North 2200 West, Salt Lake City, UT, USA, 84116 |
| 電話號碼
| +1 801 584-3600 |
| 傳真號碼
| +1 801 584-3640 |
| 公司網頁
| https://www.myriad.com |
| 員工數量
| 2700 |
| Mr. Samraat S. Raha |
President, Chief Executive Officer and Director |
美元 856.90K |
14/04/2026 |
| Mr. Mark S. Verratti |
Chief Operating Officer |
美元 622.88K |
14/04/2026 |
| Ms. Shereen Solaiman |
Chief People Officer |
-- |
14/04/2026 |
| Mr. Dale Muzzey |
Chief Scientific Officer |
美元 506.40K |
14/04/2026 |
| Mr. Benjamin R. Wheeler |
Chief Financial Officer and Principal Accounting Officer |
美元 408.49K |
14/04/2026 |
| Ms. Jennifer Fox |
Chief Legal Officer |
-- |
14/04/2026 |
| Mr. Brian J. Donnelly |
Chief Commercial Officer |
美元 350.00K |
14/04/2026 |
|
|
| Dr. Heiner Dreismann,PhD |
Independent Director |
14/04/2026 |
| Mr. Mark S. Davis |
Independent Director |
14/04/2026 |
| Ms. S. Louise Phanstiel |
Chairman of the Board |
14/04/2026 |
| Mr. Samraat S. Raha |
President, Chief Executive Officer and Director |
14/04/2026 |
| Dr. Daniel M. Skovronsky, M.D.,PhD |
Independent Director |
14/04/2026 |
| Ms. Colleen F. Reitan |
Independent Director |
14/04/2026 |
| Dr. Lee N. Newcomer, M.D. |
Independent Director |
14/04/2026 |
| Ms. Rashmi Kumar |
Independent Director |
14/04/2026 |
| Mr. Paul M. Bisaro |
Independent Director |
14/04/2026 |
|
|
|
|
